Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial - PubMed
5 hours ago
- #cardiac resynchronization therapy
- #atrial fibrillation
- #heart failure
- The CAAN-AF trial examined whether atrioventricular node ablation (AVNA) improves outcomes compared to medical rate control therapy (MRCT) in patients with heart failure and reduced ejection fraction (HFrEF), permanent atrial fibrillation (AF), and CRT-defibrillators.
- No significant difference was found in the primary endpoint of all-cause mortality and nonfatal heart failure events between AVNA and MRCT groups, with early trial termination due to futility.
- Secondary outcomes, including cardiovascular mortality, hospitalizations, ventricular arrhythmias, 6-minute walk distance, and quality of life, also showed no significant differences between treatment strategies.
- The study involved 143 randomized patients and concluded that AVNA did not reduce mortality or heart failure events compared to MRCT in this patient population.